VENLO, Netherlands, January 31, 2018 /PRNewswire/ —

• Solid Q4 results as QIAGEN achieves full-year 2017 targets:
• Q4 2017: Net sales $396.9 million (+8% actual, +5% CER); adjusted net sales rise 6% CER excluding portfolio changes vs. 5-6% CER guidance
• Q4 2017: EPS –$0.18 including impact of predominantly non-cash U.S. tax reform charge; adjusted EPS $0.43 ($0.43 CER) vs. ~$0.41-42 CER guidance
• Full-year 2017: Achieved guidance with 7% CER adjusted net sales growth excluding portfolio changes and adjusted diluted EPS of $1.27 CER
• Full-year 2017: Adjusted operating income margin improves to 26% of adjusted sales from 24% in 2016
• New $200 million share repurchase commitment through open-market repurchase
• Acquisition of STAT-Dx adds QIAstat-Dx, a next–generation PCR-based multiplex syndromic testing solution with expected European launch in second half of 2018
• QIAGEN sets 2018 outlook for further growth in adjusted net sales and adjusted EPS, reaffirms 2020 mid-term targets for improving performance

QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced results of operations for the fourth quarter and full-year 2017, delivering on goals for adjusted net sales and adjusted earnings per share while driving the global expansion of its Sample to Insight portfolio of molecular testing solutions covering the continuum from basic research to clinical healthcare.

For the full press release click here

(Link: https://corporate.qiagen.com/newsroom/press-releases/2018/20180131_q4fy2018_results?sc_lang=en)

Contacts

Investor Relations:

John Gilardi
Vice President Corporate Communications and Investor Relations
+49-2103-29 11711 and +1-240-686-2222
John.gilardi@qiagen.com

Dr. Sarah Fakih
Associate Director Investor Relations
+49-2103-29-11457
Sarah.fakih@qiagen.com

Public Relations:

Dr. Thomas Theuringer
Senior Director Public Relations and Digital Communications
+49-2103-29-11826 and +1-240-686-7425
Thomas.theuringer@qiagen.com

SOURCE Qiagen N.V.